Disease-modifying drugs for knee osteoarthritis: Can they be cost-effective?

Osteoarthritis and Cartilage

Volumn 21, Issue 5, 2013, Pages 655-667

  Losina, E ^a,b,c   Daigle, M E ^a   Suter, L G ^d   Hunter, D J ^e   Solomon, D H ^a,b   Walensky, R P ^a,b,f   Jordan, J M ^g   Burbine, S A ^a   Paltiel, A D ^d   Katz, J N ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BOSTON UNIVERSITY   (United States)

^d YALE UNIVERSITY   (United States)

^e UNIVERSITY OF SYDNEY   (Australia)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

^g UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Cost effectiveness; Disease modifying osteoarthritis drugs (DMOADs); Knee osteoarthritis; Quality of life

Indexed keywords

CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; DISEASE MODIFYING ANTIRHEUMATIC DRUG; DOXYCYCLINE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL;

ANALGESIA; ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; HUMAN; KNEE OSTEOARTHRITIS; LIFE EXPECTANCY; PAIN; PHYSIOTHERAPY; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; QUALITY OF LIFE; RISK ASSESSMENT; SENSITIVITY ANALYSIS; TOTAL KNEE REPLACEMENT; TREATMENT PLANNING;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS; ARTHROPLASTY, REPLACEMENT, KNEE; COST-BENEFIT ANALYSIS; DISEASE PROGRESSION; DRUG COSTS; FEMALE; HEALTH CARE COSTS; HUMANS; MALE; MIDDLE AGED; MODELS, ECONOMETRIC; OSTEOARTHRITIS, KNEE; PAIN; QUALITY OF LIFE; SENSITIVITY AND SPECIFICITY; UNITED STATES;

EID: 84875896668     PISSN: 10634584     EISSN: 15229653     Source Type: Journal    
DOI: 10.1016/j.joca.2013.01.016     Document Type: Article

References (71)

1. Felson D.T., Lawrence R.C., Dieppe P.A., Hirsch R., Helmick C.G., Jordan J.M., et al. Osteoarthritis: new insights. Part 1: the disease and its risk factors. Ann Intern Med Oct 17 2000, 133(8):635-646.
2. Lawrence R.C., Felson D.T., Helmick C.G., Arnold L.M., Choi H., Deyo R.A., et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum Jan 2008, 58(1):26-35.
3. Niu J., Zhang Y.Q., Torner J., Nevitt M., Lewis C.E., Aliabadi P., et al. Is obesity a risk factor for progressive radiographic knee osteoarthritis?. Arthritis Rheum Mar 15 2009, 61(3):329-335.
4. Englund M., Lohmander L.S. Risk factors for symptomatic knee osteoarthritis fifteen to twenty-two years after meniscectomy. Arthritis Rheum Sep 2004, 50(9):2811-2819.
5. von Porat A., Roos E.M., Roos H. High prevalence of osteoarthritis 14 years after an anterior cruciate ligament tear in male soccer players: a study of radiographic and patient relevant outcomes. Ann Rheum Dis Mar 2004, 63(3):269-273.
6. National Electronic Injury Surveillance System (NEISS) [accessed 04.08.12]. https://www.cpsc.gov/cgibin/NEISSQuery/home.aspx.
7. Zhang Y., Jordan J.M. Epidemiology of osteoarthritis. Clin Geriatr Med 2010, 26(3):355-369.
8. Hochberg M.C., Altman R.D., April K.T., Benkhalti M., Guyatt G., McGowan J., et al. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res (Hoboken) 2012, 64(4):465-474.
9. Zhang W., Moskowitz R.W., Nuki G., Abramson S., Altman R.D., Arden N., et al. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage Feb 2008, 16(2):137-162.
10. Richmond J., Hunter D., Irrgang J., Jones M.H., Snyder-Mackler L., Van Durme D., et al. American academy of orthopaedic surgeons clinical practice guideline on the treatment of osteoarthritis (OA) of the knee. J Bone Jt Surg Am April 1, 2010, 92(4):990-993.
11. Solomon S.D., McMurray J.J.V., Pfeffer M.A., Wittes J., Fowler R., Finn P., et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. New Engl J Med 2005, 352(11):1071-1080.
12. Silverstein F.E., Faich G., Goldstein J.L., Simon L.S., Pincus T., Whelton A., et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. JAMA 2000, 284:1247-1255.
13. Abramson S.B., Attur M., Yazici Y. Prospects for disease modification in osteoarthritis. Nat Clin Pract Rheum 2006, 2(6):304-312.
14. Reginster J.Y., Badurski J., Bellamy N., Bensen W., Chapurlat R., Chevalier X., et al. Efficacy and safety of strontium ranelate in the treatment of knee osteoarthritis: results of a double-blind, randomised placebo-controlled trial. Ann Rheum Dis Nov 9 2012.
15. Efficacy and Safety of Oral Salmon Calcitonin in Patients with Knee Osteoarthritis 2010, ClinicalTrials.gov identifier: NCT00486434. http://clinicaltrials.gov/ct2/show/NCT00486434.
16. A Long-term, Placebo-controlled X-ray Study Investigating the Safety and Efficacy of SD-6010 in Subjects with Osteoarthritis of the Knee (ITIC) 2010, ClinicalTrials.gov identifier: NCT00565812. http://clinicaltrials.gov/ct2/show/NCT00565812.
17. Hunter D.J. Pharmacologic therapy for osteoarthritis-the era of disease modification. Nat Rev Rheumatol Jan 2010, 7(1):13-22.
18. Losina E., Walensky R.P., Reichmann W.M., Holt H.L., Gerlovin H., Solomon D.H., et al. Impact of obesity and knee osteoarthritis on morbidity and mortality in older Americans. Ann Intern Med February 15, 2011, 154(4):217-226.
19. Holt H.L., Katz J.N., Reichmann W.M., Gerlovin H., Wright E.A., Hunter D.J., et al. Forecasting the burden of advanced knee osteoarthritis over a 10-year period in a cohort of 60-64 year-old US adults. Osteoarthritis Cartilage Jan 2011, 19(1):44-50.
20. Siegel J.E., Weinstein M.C., Russell L.B., Gold M.R. Recommendations for reporting cost-effectiveness analyses. JAMA October 23, 1996, 276(16):1339-1341.
21. Jordan J.M., Helmick C.G., Renner J.B., Luta G., Dragomir A.D., Woodard J., et al. Prevalence of knee symptoms and radiographic and symptomatic knee osteoarthritis in African Americans and Caucasians: the Johnston County Osteoarthritis Project. J Rheumatol Jan 2007, 34(1):172-180.
22. 2005-2006 National Health and Nutrition Examination Survey (NHANES) Data. National Center for Health Statistics (NCHS) 2006, U.S. Department of Health and Human Services, [accessed 04.08.12]. http://www.cdc.gov/nchs/nhanes/nhanes2005-2006/nhanes05_06.htm.
23. 2007-2008 National Health and Nutrition Examination Survey (NHANES) Data. National Center for Health Statistics (NCHS) 2008, U.S. Department of Health and Human Services, [accessed 04.08.12]. http://www.cdc.gov/nchs/nhanes/nhanes2007-2008/nhanes07_08.htm.
24. National Health Interview Survey (NHIS) [accessed 04.08.12]. http://www.cdc.gov/nchs/nhis.htm.
25. Arias E. United States Life Tables, 2006. National Vital Statistics Reports 2010, vol. 58. Hyattsville, Maryland 20782-2003, National Center for Health Statistics, USA.
26. Berrington de Gonzalez A., Hartge P., Cerhan J.R., Flint A.J., Hannan L., MacInnis R.J., et al. Body-mass index and mortality among 1.46 million White adults. New Engl J Med 2010, 363(23):2211-2219.
27. Centers for Disease Control and Prevention, National Center for Health Statistics Health Data Interactive. Chronic Conditions, Ages 18+: US 1997-2008, [accessed 04.08.12]. http://www.cdc.gov/nchs/hdi.htm.
28. Brazier J., Usherwood T., Harper R., Thomas K. Deriving a preference-based single index from the UK SF-36 health survey. J Clin Epidemiol 1998, 51(11):1115-1128.
29. Brandt K.D., Mazzuca S.A., Katz B.P., Lane K.A., Buckwalter K.A., Yocum D.E., et al. Effects of doxycycline on progression of osteoarthritis: results of a randomized, placebo-controlled, double-blind trial. Arthritis Rheum Jul 2005, 52(7):2015-2025.
30. Red Book: Pharmacy's Fundamental Reference: 2010 Edition 2010, Thomson Healthcare, Montvale, NJ.
31. Losina E, Weinstein AM, Reichmann WM, Burbine SA, Solomon DH, Daigle ME, et al. Lifetime risk and age of diagnosis of symptomatic knee osteoarthritis in the US. Arthritis Care & Res. 2012 [Epub].
32. Losina E., Walensky R.P., Kessler C.L., Emrani P.S., Reichmann W.M., Wright E.A., et al. Cost-effectiveness of total knee arthroplasty in the United States: patient risk and hospital volume. Arch Intern Med Jun 22 2009, 169(12):1113-1121. discussion 1121-1112.
33. Pope G.C., Kautter J., Ellis R.P., Ash A.S., Ayanian J.Z., Lezzoni L.I., et al. Risk adjustment of Medicare capitation payments using the CMS-HCC model. Health Care Financ Rev Summer 2004, 25(4):119-141.
34. Consumer Price Index Inflation Calculator 2010, [accessed 04.08.12]. http://www.bls.gov/data/inflation_calculator.htm.
35. Medicare Current Beneficiary Survey 2006, Centers for Medicare & Medicaid Services.
36. Scott D.L., Berry H., Capell H., Coppock J., Daymond T., Doyle D.V., et al. The long-term effects of non-steroidal anti-inflammatory drugs in osteoarthritis of the knee: a randomized placebo-controlled trial. Rheumatology October 1, 2000, 39(10):1095-1101.
37. Goldstein J.L., Silverstein F.E., Agrawal N.M., Hubbard R.C., Kaiser J., Maurath C.J., et al. Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor. Am J Gastroenterol 2000, 95(7):1681-1690.
38. Silverstein F.E., Graham D.Y., Senior J.R., Davies H.W., Struthers B.J., Bittman R.M., et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. Ann Intern Med August 15, 1995, 123(4):241-249.
39. Medicare Fee Schedules 2010, Centers for Medicare & Medicaid Services, [accessed 04.08.12]. http://www.cms.gov/home/medicare.asp.
40. Medicare Hospital Outpatient Prospective Payment System 2010, Centers for Medicare & Medicaid Services, [accessed 04.08.12]. http://www.cms.gov/HospitalOutpatientPPS/.
41. Medicare Hospital Inpatient Prospective Payment System 2010, Centers for Medicare & Medicaid Services, [accessed 04.08.12]. http://www.cms.gov/MedicareFeeforSvcPartsAB/03_MEDPAR.asp.
42. Van der Esch M., Heijmans M., Dekker J. Factors contributing to possession and use of walking aids among persons with rheumatoid arthritis and osteoarthritis. Arthritis Care Res 2003, 49(6):838-842.
43. Grindrod K.A., Marra C.A., Colley L., Cibere J., Tsuyuki R.T., Esdaile J.M., et al. After patients are diagnosed with knee osteoarthritis, what do they do?. Arthritis Care Res 2010, 62(4):510-515.
44. Raynauld J.P., Buckland-Wright C., Ward R., Choquette D., Haraoui B., Martel-Pelletier J., et al. Safety and efficacy of long-term intraarticular steroid injections in osteoarthritis of the knee: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum Feb 2003, 48(2):370-377.
45. Ayral X. Injections in the treatment of osteoarthritis. Best Pract Res Clin Rheumatol 2001, 15(4):609-626.
46. Katz J.N., Mahomed N.N., Baron J.A., Barrett J.A., Fossel A.H., Creel A.H., et al. Association of hospital and surgeon procedure volume with patient-centered outcomes of total knee replacement in a population-based cohort of patients age 65 years and older. Arthritis Rheum Feb 2007, 56(2):568-574.
47. Paxton E.W., Namba R.S., Maletis G.B., Khatod M., Yue E.J., Davies M., et al. A prospective study of 80,000 total joint and 5000 anterior cruciate ligament reconstruction procedures in a community-based registry in the United States. J Bone Jt Surg Am Dec 2010, 92(Suppl 2):117-132.
48. Katz J.N., Barrett J., Mahomed N.N., Baron J.A., Wright R.J., Losina E. Association between hospital and surgeon procedure volume and the outcomes of total knee replacement. J Bone Jt Surg Am Sep 2004, 86-A(9):1909-1916.
49. Healthcare Cost and Utilization Project (HCUP) Nationwide Inpatient Sample (NIS) 2009, [accessed 04.08.12]. http://hcupnet.ahrq.gov/.
50. Buntin M.B., Garten A.D., Paddock S., Saliba D., Totten M., Escarce J.J. How much is postacute care use affected by its availability?. Health Serv Res Apr 2005, 40(2):413-434.
51. Teeny S.M., York S.C., Mesko J.W., Rea R.E. Long-term follow-up care recommendations after total hip and knee arthroplasty: results of the American Association of Hip and Knee Surgeons' member survey. J Arthroplasty 2003, 18(8):954-962.
52. Bensen W.G., Fiechtner J.J., McMillen J.I., Zhao W.W., Yu S.S., Woods E.M., et al. Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial. Mayo Clinic Proc November 1, 1999, 74(11):1095-1105.
53. Healthcare Cost and Utilization Project (HCUP) Nationwide Inpatient Sample (NIS) 2008, Agency for Healthcare Research and Quality, [accessed 04.08.12]. http://hcupnet.ahrq.gov/.
54. Sullivan P.W., Ghushchyan V. Preference-based EQ-5D index scores for chronic conditions in the United States. Med Decis Making 2006, 26(4):410-420.
55. Jansen J.P., Pellissier J., Choy E.H., Ostor A., Nash J.T., Bacon P., et al. Economic evaluation of etoricoxib versus non-selective NSAIDs in the treatment of ankylosing spondylitis in the UK. Curr Med Res Opin Dec 2007, 23(12):3069-3078.
56. Kamath C.C., Kremers H.M., Vanness D.J., O'Fallon W.M., Cabanela R.L., Gabriel S.E. The cost-effectiveness of acetaminophen, NSAIDs, and selective COX-2 inhibitors in the treatment of symptomatic knee osteoarthritis. Value Health 2003, 6(2):144-157.
57. Tan-Torres Edejer T. Making Choices in Health: WHO Guide to Cost-effectiveness Analysis 2003, World Health Organization, Geneva.
58. Physician Fee Schedule Search 2010, Center for Medicare and Medicaid Services (CMS), [accessed 04.08.12]. http://www.cms.gov/pfslookup/02_PFSearch.asp.
59. Reichmann W.M., Katz J.N., Kessler C.L., Jordan J.M., Losina E. Determinants of self-reported health status in a population-based sample of persons with radiographic knee osteoarthritis. Arthritis Rheum Aug 15 2009, 61(8):1046-1053.
60. Diehr P., Patrick D.L., Spertus J., Kiefe C.I., McDonell M., Fihn S.D. Transforming self-rated health and the SF-36 scales to include death and improve interpretability. Med Care Jul 2001, 39(7):670-680.
61. Torrance G.W., Feeny D.H., Furlong W.J., Barr R.D., Zhang Y., Wang Q. Multiattribute utility function for a comprehensive health status classification system. Health Utilities Index Mark 2. Med Care Jul 1996, 34(7):702-722.
62. Braithwaite R.S., Meltzer D.O., King J.T., Leslie D., Roberts M.S. What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule?. Med Care Apr 2008, 46(4):349-356.
63. Ubel P.A., Hirth R.A., Chernew M.E., Fendrick A.M. What is the price of life and why doesn't it increase at the rate of inflation?. Arch Intern Med Jul 28 2003, 163(14):1637-1641.
64. Hidden Costs, Value Lost: Uninsurance in America 2003, Institute of Medicine of the National Academies.
65. Neogi T., Felson D., Niu J., Nevitt M., Lewis C.E., Aliabadi P., et al. Association between radiographic features of knee osteoarthritis and pain: results from two cohort studies. BMJ 2009, 339:b2844.
66. Felson D.T., Chaisson C.E., Hill C.L., Totterman S.M., Gale M.E., Skinner K.M., et al. The association of bone marrow lesions with pain in knee osteoarthritis. Ann Intern Med Apr 3 2001, 134(7):541-549.
67. Hunter D.J., Lo G.H., Gale D., Grainger A.J., Guermazi A., Conaghan P.G. The reliability of a new scoring system for knee osteoarthritis MRI and the validity of bone marrow lesion assessment: BLOKS (Boston-Leeds Osteoarthritis Knee Score). Ann Rheum Dis February 1, 2008, 67(2):206-211.
68. Reichmann W.M., Maillefert J.F., Hunter D.J., Katz J.N., Conaghan P.G., Losina E. Responsiveness to change and reliability of measurement of radiographic joint space width in osteoarthritis of the knee: a systematic review. Osteoarthritis Cartilage. May 2011, 19(5):550-556.
69. Osteoarthritis Initiative (OAI) [accessed 04.08.12]. http://oai.epi-ucsf.org/datarelease/default.asp.
70. Wise B.L., Felson D.T., Clancy M., Niu J., Neogi T., Lane N.E., et al. Consistency of knee pain and risk of knee replacement: the multicenter osteoarthritis study. J Rheumatol April 15, 2011, 38(7):1390-1395.
71. Healthcare Cost and Utilization Project (HCUP) Nationwide Inpatient Sample (NIS) 1999-2009, [accessed 04.08.12]. http://hcupnet.ahrq.gov/.